



101st Annual Meeting Accreditation Information

Target Audience

The educational design of the AANP's Annual Meeting addresses the needs of physicians and scientists in the field of neuropathology who are involved in the diagnosis and/or treatment of patients with neurological disorders.

Statement of Need

The purpose of this activity is to advance medical and scientific knowledge, understanding, and competence in the practice of neuropathology. The practice of neuropathology is understood to include diagnosis of diseases of the nervous system, scientific investigation into their causes, and teaching of neuropathology principles to colleagues and trainees.

Learning Objectives

Upon completion of this activity, participants should be able to:

1. Discuss recent advances in the field of neuropathology that impact research and practice.
2. Cite 2-3 examples of new information on the underlying etiologies and mechanisms of neurologic disease.
3. Explain how to translate the latest developments in neuropathology into clinical practice.

Physician Accreditation Statement

The American Association of Neuropathologists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

The American Association of Neuropathologists designates this Other activity (blended live activity and enduring material) for a maximum of 25.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Pathology (ABPath) Continuous Certification

This activity is registered for American Board of Pathology Lifelong Learning (CME) credit.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to satisfy the Lifelong Learning (CME) requirements in the American Board of Pathology's (ABPath) Continuous Certification (CC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting credit.

Successful completion of the CME activity allows the participant to earn up to 25.75 Lifelong Learning (CME) credits.

To receive credit, you must complete the evaluation, claim credit commensurate with the extent of your participation in the activity, and provide your ABPath Diplomate ID and Date of Birth (MM/DD). Your information will be shared with the ABPath through the ACCME Program and Activity Reporting System (PARS).

Instructions to Receive CME Credit

All attendees should complete the post-test and evaluation for the *Special Course* and the *Presidential Symposium* evaluation (listed below the agendas on the meeting website for Thursday and Sunday), if those portions of the meeting were attended.

All attendees must also complete the *Overall Conference Survey*. Detailed instructions for claiming CME credit are posted under Evals/Credit on the event website. You must be logged into the event website in order to access the evaluations and claim credit. You must claim credit by **September 30, 2025**.

The chart below outlines which portions of the 101st Annual Meeting are offered for CME credit and the maximum number of credit hours a physician can earn for each portion accredited for *AMA PRA Category 1 Credit™*. As this is an “Other activity” format you may claim credit based on your attendance at either the live session or for watching the recorded content up through **September 30, 2025**, when recorded content will expire. However, you may not claim credit more than once for a given session. Those sessions that were recorded are marked with an asterisk (*).

Activity	CME Credit Hours
*Special Course	7.25
*Korey Lecture	1.00
*DeArmond Lecture	1.00
*Parisi Lecture	1.00
Scientific Sessions	8.00
*What Every Neuropathologist Needs to Know	1.00
*Diagnostic Slide Session	3.00
*Presidential Symposium inclusive of Moore Lecture	3.5
Total	25.75

Contact Information

For questions regarding the accreditation of this meeting and the process for completing the evaluations and claiming credit, please contact the AANP’s Accredited CE Coordinator, Sarah Porter, via email at sporter@aoeconsulting.com or via phone at: (713) 820-0446.

Disclosure Information

Disclosure of Commercial Support:

This activity is not supported by an educational grant.

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The American Association of Neuropathologists does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Disclosure of Relevant Financial Relationships:

The American Association of Neuropathologists (AANP) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by AANP are required to disclose all financial relationships with any ineligible company within the past 24 months to the AANP in accordance with the *Standards for Integrity and Independence in Accredited CE* in advance of delivery of the activity to learners. The content of this activity was vetted by the AANP Education Committee to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by the AANP.

Planners and Managers

The following planners and managers have ***no relevant financial relationships*** with ineligible companies:

Kenneth **Aldape**, MD; Sanda **Alexandrescu**, MD; Malak **Althgafi**, MD, MBA; Douglas **Anthony**, MD, PhD; Knarik **Arkun**, MD, FACP; Maria Beatriz **Lopes**, MD, PhD; Nicole **Becker**, MD; Chunyu **Cai**, MD, PhD; Sandra **Camelo-Piragua**, MD; Gregory **Chamberlin**, MD; Jason **Chiang**, MD, PhD; Rati **Chkheidze**, MD; Kyle **Conway**, MD; Matthew **Cykowski**, MD; John **Donahue**, MD; Rebecca **Folkerth**, MD; Caterina **Giannini**, MD, PhD; Murat **Gokden**, MD; Maria **Gubbiotti**, MD, PhD; Brent **Harris**, MD, PhD; William **Harrison**, MD; Eyas **Hattab**, MD; Annie **Hiniker**, MD, PhD; Cherry **Ho**, MD, PhD; Eric **Huang**, MD, PhD; Pouya **Jamshidi**, MD; Cougar **Jaramillo**, MD; Heather **Jarrell**, MD; Lawrence **Kenyon**, MD, PhD; Julia **Kofler**, MD; Jesse **Kresak**, MD; Maria **Martinez-Lage**, MD; Michael **Miller**, MD, PhD; Bret **Mobley**, MD; Rachel **Multz**, MD; Kathy **Newell**, MD; Aivi **Nguyen**, MD; Angelica **Oviedo**, MD; Sarah **Porter**, CHCP; Michael **Punsoni**, MD; Veena **Rajaram**, MD; Hasini **Reddy**, MD; Marie **Rivera-Zengotita**, MD; Angela **Viaene**, MD, PhD; Matthew **Wood**, MD, PhD

The following planners and managers have ***relevant financial relationships*** with ineligible companies:

Karra Jones , MD, PhD	Consulting Fee: Astellas Gene Therapies
Edward Lee , MD, PhD	Consulting Fee: WaveBreak Therapeutics; Lilly
John "Jack" Lee , MD, PhD	Patent: Holds joint patents on a drug for treatment of Alzheimer's disease/senile dementia and anxiety disorders with others and Cornelli Consulting, Milan, Italy (No royalties associated – patent tied to research in early clinical stages); Advisory Board: Ceremark Pharma, Inc.
CJ Lucas , MD	Consulting Fee: Servier Pharmaceuticals
Andrew Teich , MD, PhD	Contracted Research: Regeneron Pharmaceuticals; Stock Shareholder: Ionis Pharmaceuticals, Biogen Pharmaceuticals

Faculty, Authors, Content Developers

The following faculty, authors, and content developers have ***no relevant financial relationships*** with ineligible companies:

Kenneth **Aldape**, MD, PhD; Christopher **Allen**, DO; Douglas **Anthony**, MD, PhD; Alberto **Ardura-Fabregat**, MD, MSc, PhD; Nicole **Becker**, MD; Sarra **Belakhousa**, MD; Stephanie **Beldick**, MD, MSc; Kevin **Bieniek**, PhD; Samuel **Bobholz**, PhD; Yiran **Cheng**; Jason **Chiang**, MD, PhD; PJ **Cimino**, MD, PhD; Kyle **Conway**, MD; Brendan **Crumley**, MD, MPH; Chris **Dampier**, MD; Marc **Del Bigio**, MD PhD FRCPC; Ashley **Denney**, MD, PhD; Aishwarya **Dhall**, MSc; Phedias **Diamandis**, MD, PhD, FRCPC; David **Ellison**, MD PhD; Glaucia **Fernandes**, PhD; Yael **Fisher**, MD; Itzhak **Fried**, MD, PhD; David **Garcia**, PhD; Nikhil **Ghayal**, BS; Bernardino **Ghetti**, MD; Jeffrey **Golden**, MD; Angelique **Gonzalez**, BS; Ekin **Guney**, MD; Toshiro **Hara**, PhD; Gunnar **Hargus**, MD PhD; Husham **Hashim**, MD; Annie **Hiniker**, MD, PhD; Jacob A. **Houpt**, MD; Jenny **Hsieh**, PhD; Jason **Huse**, MD, PhD; Pramath **Kakodkar**, MB, BCh, BAO; Michael **Keeney**, MD; Abdelhakim **Khellaf**, MD, CM; Lakshmi Shree Kulumani **Mahadevan**, MD; Gulce **Kureli**, MD-PhD; Peter **LaViolette**, PhD; Adriana **May**, MD; David **Meredith**, MD, PhD; Marcus **Milani**, MS; Michael **Miller**, MD, PhD; Edwin **Monuki**, MD, PhD; Rachel **Multz**, MD; Rakesh **Nanjappa**, PhD; MacLean **Nasrallah**, MD, PhD; Peter **Nelson**, MD/PhD; Joyce **Opara**, MD; Ling-Lin (Emily) **Pai**, MD, PhD; Thomas **Pearce**, MD, PhD; Sandra **Perez**, MD; David **Priemer**, MD; Sharika **Rajan**, MD; Timothy **Richardson**, DO, PhD; Lorraina **Robinson**, DO, MS; John **Robinson**, BS; Rocio Fernanda **Rodriguez Reyes**, MD; Aaron **Rosado**, MD PhD; Matthew **Rose**, MD/PhD; Agrima **Sharma**; Mehar **Sharma**, MD, FRC PATH; Heather **Smith**, MD/PhD; Erin **Stephenson**, MD, PhD; Mariko **Taga**, PhD; Cyrus **Takahashi**, MD, PhD; Emily **Teague Smith**, MD; Zeynep **Temerit Kumm**, MD; Nadejda **Tsankova**, MD/PhD; Angela **Viaene**, MD, PhD; M. Adelita **Vizcaino**, MD; Claire **Voyles**; Jamie **Walker**, MD, PhD; Yuxiu **Wang**, MD; Hsin-Pei **Wang**, BS; Marius **Wernig**, MD; Matthew **Wood**, MD, PhD; Kenrick **Wysong**, MD; Kevin **Zhang**, MD

The following faculty, authors, and content developers have ***relevant financial relationships*** with ineligible companies:

Thomas Beach , MD, PhD, FRCPC	Contracted Research: Lantheus Holdings
Andrea Franson , MD	Contracted Research: Regeneron, Day One Biopharmaceuticals, Eli Lilly and Company; Consulting Fee: Day One Biopharmaceuticals, Alexion, SpringWorks Therapeutics
Cynthia Hawkins , MD, PhD	Contracted Research: Servier Canada
Andrew McKeon , MBBCh, MD	Patents and Royalties: GFAP and MAP1B-IgGs; Patents Pending: PDE10A, Septins-5 and -7, and KLHL11-IgGs
Julie Miller , MD, PhD	Consulting Fee: Servier
Christopher Mount , MD, PhD	Stock Shareholder: Cargo Therapeutics; Licensed intellectual property: Cargo Therapeutics
Andrew Teich , MD, PhD	Contracted Research: Regeneron Pharmaceuticals; Stock Shareholder: Ionis Pharmaceuticals, Biogen Pharmaceuticals
Itay Tirosh , PhD	Consulting Fee: Immunitas Therapeutics, Cellyrix Therapeutics, Compugen Ltd.
Tracy Young-Pearse , PhD	Consulting Fee: Flagship Pioneering

Moderators

The following moderators have ***no relevant financial relationships*** with ineligible companies:

Jared **Ahrendsen**, MD, PhD; Douglas **Anthony**, MD, PhD; Sandra **Camelo-Piragua**, MD ; Jason **Chiang**, MD, PhD; Kyle **Conway**, MD; Marcello **DiStasio**, MD, PhD; Brittany **Dugger**, PhD; Caterina **Giannini**, MD, PhD; Maria **Gubbiotti**, MD, PhD; Anita **Huttner**, MD; Michael **Miller**, MD, PhD; Kathy **Newell**, MD; Melike **Pekmezci**, MD, PhD; Rick **Perrin**, MD, PhD; Emile **Pinarbasi**, MD, PhD; Nadia **Tsankova**, MD, PhD; Angela **Viaene**, MD, PhD

The following moderators have ***relevant financial relationships*** with ineligible companies:

Lucas Calixto-Hope , MD	Consulting Fees: Servier Pharmaceuticals
Meaghan Morris , MD, PhD	Consulting Fees: SciNeuro Pharmaceuticals
Peter Pytel , MD	Consulting Fees: Servier Pharmaceuticals

Content Reviewers

The following content reviewers have ***no relevant financial relationships*** with ineligible companies:

Chunyu **Cai**, MD, PhD; Pouya **Jamshidi**, MD; Lawrence **Kenyon**, MD, PhD; Gregory **Chamberlin**, MD; Katie **Propst**, PhD; Veena **Rajaram**, MD Marie **Rivera-Zengotita**, MD

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.